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We would like to thank Drs. Jandeleit-Dahmand Schmidt (1) for their interesting com-ments regarding our study examining the roleof the Nox2 isoform of NADPH oxidase in
insulin resistance–related endothelial cell dysfunction (2).
We would also like to congratulate them on their own elegant
and comprehensive piece of work examining the role of the
Nox isoforms Nox1, Nox2, and Nox4 in the development
of advanced type 1 diabetes–related atherosclerosis (3).
Based on their ﬁndings that Nox1 may be more impor-
tant in diabetes-related atherosclerosis than other iso-
forms of NADPH oxidase, the authors raise concerns
regarding our conclusions that Nox2 has a critical role in
insulin resistance–related endothelial dysfunction. They
also reported that holoinsufﬁciency of Nox2 in mice ren-
dered diabetic using streptozotocin led to a substantial
mortality rate.
It is important to recognize the fundamental differences
between our studies and those of Jandeleit-Dahm and
colleagues (3). Jandeleit-Dahm and colleagues and You
et al. (4) administered streptozotocin to render mice di-
abetic. In the article by Jandeleit-Dahm and colleagues,
this led to a severe model of advanced insulin-deﬁcient
diabetes leading to substantial weight loss, hyperglycemia,
and increased triglycerides and cholesterol. Moreover, it is
well established that streptozotocin-induced diabetes leads
to immune dysfunction (5), which may account for the
ﬁndings reported by Jandeleit-Dahm and colleagues re-
garding mortality in Nox2 deﬁcient mice. A comparison
between our study and that of Jandeleit-Dahm and col-
leagues is therefore difﬁcult to make.
In our studies, we used two complementary models
of human disease before the onset of hyperglycemia with
the ApoE gene intact: 1) endothelium-speciﬁc insulin re-
sistance (mice expressing a mutant human insulin receptor
speciﬁcally in the endothelium) and 2) whole-body insulin
resistance (mice with haploinsufﬁciency of the insulin re-
ceptor). We found no increase in Nox1 or Nox4 expression
in endothelial cells from these mice, but did demonstrate
increased Nox2. Mice with endothelium-speciﬁc insulin
resistance deﬁcient in Nox2 or mice treated with the Nox2
inhibitor gp91ds-tat did not have increased mortality.
In our studies, acute and chronic inhibition of Nox2 led
to restoration of endothelial vasorelaxation and super-
oxide to the levels seen in wild-type littermates, providing
compelling evidence that Nox2 is a critical determinant
of endothelial dysfunction in insulin resistance. We did
not examine the role of Nox2 in severe hyperglycemia–
induced endothelial dysfunction and atherosclerosis. In
the commentary to our article, Dr. Symons (6) raised a
number of suggestions for future work, one of which
was to assess the role of Nox2 in insulin resistance–
related atherosclerosis; we are currently pursuing this
avenue of work. The work from the laboratories of Drs.
Jandeleit-Dahm and Schmidt and our own highlight the
complexity of diabetes-related vascular disease and il-
lustrate that a “one size ﬁts all” approach is not appro-
priate for the treatment of this lethal complication of
diabetes.
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